Drug Profile
WIN 901X
Alternative Names: WIN-901; WIN901XLatest Information Update: 19 Dec 2019
Price :
$50
*
At a glance
- Originator Whanin Pharmaceutical
- Class Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 19 Dec 2019 No development reported - Phase-II for Asthma in South Korea (PO)
- 22 Feb 2016 Phase-II development is ongoing in South Korea (Whanin Pharm pipeline, February 2016)
- 30 Nov 2013 Whanin Pharmaceutical Company completes a phase II trial in Asthma in South Korea (NCT01820481)